An ATR-PrimPol pathway confers tolerance to oncogenic KRAS-induced and heterochromatin-associated replication stress
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
An ATR-PrimPol pathway confers tolerance to oncogenic KRAS-induced and heterochromatin-associated replication stress ; volume:14 ; number:1 ; day:17 ; month:8 ; year:2023 ; pages:1-22 ; date:12.2023
Nature Communications ; 14, Heft 1 (17.8.2023), 1-22, 12.2023
- Creator
-
Igarashi, Taichi
Mazevet, Marianne
Yasuhara, Takaaki
Yano, Kimiyoshi
Mochizuki, Akifumi
Nishino, Makoto
Yoshida, Tatsuya
Yoshida, Yukihiro
Takamatsu, Nobuhiko
Yoshimi, Akihide
Shiraishi, Kouya
Horinouchi, Hidehito
Kohno, Takashi
Hamamoto, Ryuji
Adachi, Jun
Zou, Lee
Shiotani, Bunsyo
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41467-023-40578-2
- URN
-
urn:nbn:de:101:1-2024020211021310722101
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:30 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Igarashi, Taichi
- Mazevet, Marianne
- Yasuhara, Takaaki
- Yano, Kimiyoshi
- Mochizuki, Akifumi
- Nishino, Makoto
- Yoshida, Tatsuya
- Yoshida, Yukihiro
- Takamatsu, Nobuhiko
- Yoshimi, Akihide
- Shiraishi, Kouya
- Horinouchi, Hidehito
- Kohno, Takashi
- Hamamoto, Ryuji
- Adachi, Jun
- Zou, Lee
- Shiotani, Bunsyo
- SpringerLink (Online service)
Other Objects (12)
Oncogenic KRAS mutation confers chemoresistance by upregulating SIRT1 in non-small cell lung cancer
HDAC Inhibitor-Induced acetylation of KRAS confers a pro-oncogenic effect limiting treatment response in colorectal cancer
Immune modulatory effects of oncogenic KRAS in cancer
Oncogenic KRAS promotes malignant brain tumors in zebrafish
Oncogenic KrasG12D causes myeloproliferation via NLRP3 inflammasome activation
Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges
Oncogenic KRAS renders cells resistant to ferroptosis by upregulating FSP1
Oncogenic KRAS supports pancreatic cancer through regulation of nucleotide synthesis
Controlling oncogenic KRAS signaling pathways with a Palladium-responsive peptide
Oncogenic KRAS supports pancreatic cancer through regulation of nucleotide synthesis
Oncogenic KrasG12D causes myeloproliferation in leukaemia via NLRP3 inflammasome activation
KRAS Q61H Mutation Confers Cancer Cells with Acquired Resistance to SHP2 Inhibition
Oncogenic KRAS mutation confers chemoresistance by upregulating SIRT1 in non-small cell lung cancer
HDAC Inhibitor-Induced acetylation of KRAS confers a pro-oncogenic effect limiting treatment response in colorectal cancer
Immune modulatory effects of oncogenic KRAS in cancer
Oncogenic KRAS promotes malignant brain tumors in zebrafish
Oncogenic KrasG12D causes myeloproliferation via NLRP3 inflammasome activation
Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges
Oncogenic KRAS renders cells resistant to ferroptosis by upregulating FSP1
Oncogenic KRAS supports pancreatic cancer through regulation of nucleotide synthesis
Controlling oncogenic KRAS signaling pathways with a Palladium-responsive peptide
Oncogenic KRAS supports pancreatic cancer through regulation of nucleotide synthesis
Oncogenic KrasG12D causes myeloproliferation in leukaemia via NLRP3 inflammasome activation
KRAS Q61H Mutation Confers Cancer Cells with Acquired Resistance to SHP2 Inhibition
Oncogenic KRAS mutation confers chemoresistance by upregulating SIRT1 in non-small cell lung cancer
HDAC Inhibitor-Induced acetylation of KRAS confers a pro-oncogenic effect limiting treatment response in colorectal cancer
Immune modulatory effects of oncogenic KRAS in cancer
Oncogenic KRAS promotes malignant brain tumors in zebrafish
Oncogenic KrasG12D causes myeloproliferation via NLRP3 inflammasome activation
Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges
Oncogenic KRAS renders cells resistant to ferroptosis by upregulating FSP1
Oncogenic KRAS supports pancreatic cancer through regulation of nucleotide synthesis
Controlling oncogenic KRAS signaling pathways with a Palladium-responsive peptide
Oncogenic KRAS supports pancreatic cancer through regulation of nucleotide synthesis
Oncogenic KrasG12D causes myeloproliferation in leukaemia via NLRP3 inflammasome activation